NY-WEA-GRP-POLICIES
5.5.2022 13:07:06 CEST | Business Wire | Press release
The Women’s Entrepreneurship Accelerator (WEA) today announced the publication of an Advocacy Brief titled “Procurement’s strategic value: Why gender-responsive procurement makes business sense” which presents compelling evidence of the benefits for strengthening the participation of women in private sector supply chains in realizing inclusive economic growth and sustainable development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220505005120/en/
Developed by UN Women and funded by Mary Kay Inc. in support of WEA, the Advocacy Brief highlights the rollback on progress in achieving gender equality as a result of the COVID-19 pandemic, as well as how increasing levels of economic insecurity, supply chain interruptions and unprecedented climate and environmental shocks have a disproportionate impact on women given their unequal position in society.
The publication echoes previous studies that show that economies have better opportunities to grow and are more resilient to crises if women and men have equal rights.1 However, huge challenges remain. Women entrepreneurs continue to face many obstacles including lack of access to capital on both domestic and international markets; fewer entrepreneurship networks compared with men; and policies that discourage female labor market participation.2 Globally, while one in three businesses are owned by women, 3 women only win an estimated one percent of the global spend of large corporations .4 Unequal gender laws also hinder women’s economic opportunity. For instance, nearly 2.4 billion women of working age still do not enjoy the same economic rights as men.5 Despite these statistics, women entrepreneurs remain a solution for many challenges the world faces today and the evidence shows there is a direct correlation between an increase in women entrepreneurship and economic growth, sustainable development, and more inclusive and resilient societies.6
The data presented in the Advocacy Brief outline how the adoption of gender-responsive (GRP) policies and practices through procurement processes is a strategic lever to mitigate the impact of the structural barriers women face and at the same time improve businesses and strengthen economies. The Advocacy Brief cautions that failing to adopt GRP is a wasted opportunity. The evidence is clear. Reducing gender inequalities is good for business and is smart economics.
“Gender-responsive procurement affects corporate profitability, risk mitigation, innovation, and sustainability. When women entrepreneurs are excluded from the procurement pipeline, companies risk leaving a considerable amount of talent, creativity, and expertise on the table. GRP is a winning business strategy as well as a powerful catalyst for change,” said Deborah Gibbins, Chief Operating Officer, Mary Kay, Inc., and inceptor of WEA.
To inform the Advocacy Brief, UN Women engaged over 350 stakeholders in 2021, of which over 150 private sector companies were represented, and incorporated 7 case studies on companies’ procurement journeys to create an evidence base for why businesses should adopt gender-responsive procurement. Stakeholder engagement took the form of interviews, a survey and a community of practice, which benefitted from dissemination across a wide range of networks, including the membership and networks of UN Global Compact’s (UNGC).
Companies reported that GRP leads to:
- Increased revenue and reduced procurement spend,
- Greater supplier availability and resilience,
- Strengthened brand reputation,
- More innovation and adaptability,
- Improved service delivery due to greater agility, and
- Strengthened markets through local economic development and inclusive growth.
As the Advocacy Brief notes “inclusive and sustainable development is paramount for businesses seeking to both stabilize themselves in a volatile economy and benefit from its future growth. Widening gender inequalities hurt all companies, including women entrepreneurs vital to robust and resilient supply chains and the businesses that rely on them.”
Reflecting the increased focus on environmental, social and governance (ESG) issues by companies, the Advocacy Brief notes how “the implementation of GRP allows companies to practice and institutionalize ESG values and importantly contribute to women’s empowerment and the Sustainable Development Goals (SDGs). Through the adoption of GRP principles, businesses can make progress towards multiple goals, including gender equality (SDG 5) and reduced inequalities (SDG 10) in addition to responsible consumption and production (SDG 12), eliminating poverty (SDG 1) and decent work and economic growth (SDG 8).”
“Achieving the Sustainable Development Goals is not something that can be done by women alone, or by business alone, or by government alone. The only way for us to be able to really make progress is if all – business included – work together towards a common purpose,” said Anita Bhatia , Assistant Secretary-General and Deputy Executive Director of UN Women.
Through the release of this report WEA calls on the private sector to adopt GRP strategies and integrate women into global value chains as a vehicle to advance the SDGs. This makes business sense while at the same time advances women’s economic empowerment which benefits economies and societies at large.
The Advocacy Brief is available here .
About the Women’s Entrepreneurship Accelerator
The Women’s Entrepreneurship Accelerator (WEA) is a multi-stakeholder partnership on women’s entrepreneurship established during UNGA 74. It convenes six UN agencies, International Labour Organization (ILO), International Trade Centre (ITC), International Telecommunication Union (ITU), UN Development Programme (UNDP), UN Global Compact (UNGC), UN Women and Mary Kay Inc. to empower 5 million women entrepreneurs by 2030.
The ultimate goal of the initiative is to maximize the development impact of women entrepreneurship in achieving the Sustainable Development Goals (SDGs) by creating an enabling ecosystem for women entrepreneurs around the world. The Accelerator exemplifies the transformational power of a multi-partnership of unique magnitude to harness the potential of women entrepreneurs. Learn more at we-accelerate. Follow us: Twitter (We_Accelerator), Instagram (@we_accelerator), Facebook (@womensentrepreneurshipaccelerator), LinkedIn (@womensentrepreneurshipaccelerator)
1 World Development Report. 2012: Gender Equality and Development: https://openknowledge.worldbank.org/handle/10986/4391 . |
2 European Commission and OECD Policy Brief on Women’s Entrepreneurship. 2017: https://www.oecd.org/cfe/smes/Policy-Brief-on-Women-s-Entrepreneurship.pdf |
3 World Bank. 2020. Enterprise Surveys, World Bank Gender Data Portal: https://www.worldbank.org/en/data/datatopics/gender |
4 Vazquez, E.A. and A.J. Sherman. 2013. Buying for Impact: How to Buy from Women and Change the World. Charleston, USA: Advantage |
5 World Bank Group. 2022.. Women, Business and the Law 2022. Washington, DC: World Bank |
6 UN Women Facts and Figures: Economic Empowerment: https://www.unwomen.org/en/what-we-do/economic-empowerment/facts-and-figures |
View source version on businesswire.com: https://www.businesswire.com/news/home/20220505005120/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
